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ABSTRACT
Objective: A simple, novel, sensitive, and rapid high-performance thin-layer chromatographic (HPTLC) method has been developed and validated for 
quantitative determination of fenofibrate in bulk and formulations.
Methods: The chromatographic development was carried out on HPTLC plates precoated with silica gel 60 F254 using a single solvent dichloromethane 
as a simple mobile phase. Densitometric detection was carried out at 292 nm.
Results: Rf value of drug was found to be 0.33±0.02. The method was validated as per International Conference on Harmonization Guideline with 
respect to linearity, accuracy, precision, and robustness. The calibration curve was found to be linear over a range of 20–400° ng band−1° with a 
regression coefficient of 0.999. The method has proved high sensitivity and specificity.
Conclusion: Proposed densitometric method was found to be new, simple, and economic for routine quantification of fenofibrate in bulk and 
pharmaceutical formulation.
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INTRODUCTION
Fenofibrate is the lipid regulating drug. Chemically, it is propan-2-
yl2-[4-(4-chlorobenzoyl) phenoxy]-2-methyl propionate. Fenofibrate 
increases lipolysis and elimination of triglyceride-rich particles from 
plasma by activating lipoprotein lipase and reducing production of 
apoprotein C-III (an inhibitor of lipoprotein lipase activity) [1,2]. It is 
official in British pharmacopoeia [3]. The literature survey showed 
that there are some analytical methods reported for fenofibrate 
(Fig. 1) like spectrophotometric [4-8], high-performance liquid 
chromatographic [9-16], high-performance thin-layer chromatographic 
(HPTLC) [17,18], and polarography analysis [19] either individually or 
in combination with other drug/s.
The present research manuscript describes a novel, simple, 
economical, accurate, and rapid HPTLC method developed in single 
solvent and validated in accordance with International Conference on 
Harmonization (ICH) Guidelines Q2 (R1) [20], for quantification of 
fenofibrate as a bulk drug and in its tablet dosage form.
METHODS
The fenofibrate pure standard was supplied by Emcure Pharmaceuticals 
Pvt. Ltd., Pune. Faint 160 mg tablets (Franco-Indian Pharmaceuticals 
Pvt. Ltd.); labeled to contain 160 mg fenofibrate, were obtained from 
the market. Analytical reagent grade chemicals were procured from 
Company Merck Specialties Pvt. Ltd. (Mumbai, India). Precoated silica 
gel HPTLC plates 60 F254 (E. Merck, Darmstadt, Germany) were used in 
the research.
Instrumentation, chromatographic conditions
The HPTLC instrument comprised a Linomat V sample applicator with 
a 100 μl Camag syringe with a TLC III scanner having WinCats Software 
Version 1.4.4. (Camag, Muttenz, Switzerland). The slit dimension 
was retained at 5×0.45 mm and a scanning speed of 10 mm/s was 
maintained. Prewashed HPTLC plates were activated at 120°C for 
15 min before analysis.
HPTLC plates were then developed in a Camag 20×10 cm twin trough 
chamber (Camag, Muttenz, Switzerland) with 20 ml mobile phase 
comprising only dichloromethane. The optimized chamber saturation 
time for solvent system was 15 min at room temperature (25±2°C). 
The length of chromatographic run was 80 mm. After chromatographic 
development, plates were dried in an air current. Densitometric 
scanning was performed in the reflectance-absorbance mode at 292 nm 
by Camag TLC Scanner III using WinCats Software Version 1.4.4.
Preparation of standard stock solutions
Standard stock solution of fenofibrate was prepared individually 
by dissolving 10 mg of standard drug in 10 ml methanol to get 
concentration of 1000 μg/ml and from this 1 ml further diluted to get 
100 μg/ml concentrations.
Selection of detection wavelength
Fenofibrate showed significant absorbance at 292 nm and thus was 
selected for densitometric analysis (Fig. 2).
Preparation of sample solutions
For the study of marketed tablet dosage form, 20 tablets were accurately 
weighed. The average weight was assessed and tablets were crushed to 
get fine powder. Powder equivalent to 5 mg of fenofibrate was weighed 
and shifted to the volumetric flask (50 ml) containing 20 ml methanol. 
The solution was sonicated for 15 min, diluted up to the mark with 
solvent methanol. The solution was filtered through Whatman filter 
paper (No. 41). The resulting solution is used for further study.
Assay validation
The proposed HPTLC method was validated as per the guidelines of the 
([ICH] Q2 [Rl]) for various parameters.
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Linearity and range
On the HPTLC plate, a stock solution was applied in the concentration of 
20–400 ng band−1 of fenofibrate to evaluate linearity. The graph of peak 
area versus concentration was plotted. Least square linear regression 
analysis was done. The correlation coefficient, intercept, and slope 
were calculated.
Sensitivity
Limit of detection (LOD) and limit of quantitation (LOQ) was calculated 
using formula 3.3 σ/S and 10 σ/S, respectively, where σ is the standard 
deviation of the response (y-intercept) and S is the slope of the linearity 
plot.
Specificity
The peak purity for fenofibrate was assessed by comparing ultraviolet 
(UV) spectrum acquired at the start (S), apex (M), and end (E) of the 
peak obtained from the scanning of the band.
Precision studies
Precision was calculated by intra- and inter-day precision studies. 
100 ng band−1 fenofibrate sample was analyzed 6 times on the similar 
day to find out any differences in the results. Interday precision study 
was done on 3 successive days.
Accuracy studies
By estimating recovery of fenofibrate by the standard addition 
method, the accuracy was determined. The samples were spiked 
at three levels with 80, 100, and 120% of 100 ng band−1 of the 
fenofibrate standard solution. Recovery was assessed from the 
following equation:
([Spiked concentration-mean concentration]/spiked concentration)×100
Robustness studies
The effect of small but deliberate variations in method parameters 
such as the volume and composition of the mobile phase, time from 
spotting to development, and development to scanning were evaluated 
in this study. Only one parameter was varied at a time. 100 ng band−1 
concentration of fenofibrate was used in six replicates to study 
robustness of the method. The standard deviation of peak areas and % 
relative standard deviation (RSD) was determined.
RESULTS AND DISCUSSION
Chromatographic development
Different solvent systems were tried, to accomplish the Rf value in the 
range 0.2–0.8, and minimum resolution Rs ≥1.5. Finally, the mobile 
phase consisting of only dichloromethane was selected for obtaining 
sharp peak and promising results. The retention factors were found to 
be 0.33±0.02 for fenofibrate (Fig. 3).
Validation of the method
Linearity
The analyte response was linear (r2=0.999) for fenofibrate over the 
concentration range between 20 and 400 ng band−1. The results were 
shown in Table 1. Calibration curve was constructed as described and 
showed acceptable accuracy and precision over a wide concentration 
range. Results demonstrate that an excellent correlation between 
the absorbance and concentration of fenofibrate drug substances. To 
ascertain linearity, residual analysis was performed (Fig. 4).
Fig. 1: Chemical structure of fenofibrate
Fig. 2: Spectrum obtained from standard solution of fenofibrate
Table 1: Linear regression data for the calibration curves (n=6)
Parameters




Confidence limit of slopea 20.84–21.65
Confidence limit of intercepta 409.19–575.90
Sy.x 33.75
a: 95% confidence limit, Sy.x: Standard deviation of residuals from line
Fig. 3: Densitogram obtained from standard solution of 
fenofibrate scanned at 292 nm
Fig. 4: Concentration residual plot of fenofibrate
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Sensitivity
The LOD was found to be 5.24 ng band−l for fenofibrate. The LOQ 
for fenofibrate was found to be 15.89 ng band−l, representing good 
sensitivity of the method.
Specificity
The peak purity for fenofibrate was assessed by comparing UV 
spectrum acquired at the start (S), apex (M), and end (E) of the peak 
obtained from the scanning of band, that is, r (S, M)=0.998, 0.998 and 
r (M, E)=0.998, 0.998, respectively. Peak purity data showed that peak 
obtained for fenofibrate was pure and method is specific.
Precision
Intra- and inter-day variation in estimation of fenofibrate (Table 2) 
showed that the % RSD was <2% during the analysis. These low values 
of RSD show that the precision of the method is good.
Accuracy
The study of accuracy reveals influences of additives that are usually 
present in the dosage forms on the quantitative parameters. The 
recovery study data presented in Table 3 indicates that the accuracy 
of the quantification of fenofibrate was more than 98%, which indicate 
that the proposed simultaneous densitometric method is reliable for 
the estimation of fenofibrate in the marketed formulation used in the 
study.
Robustness studies
The % RSD of peak areas was calculated for each parameter and was 
found to be <2% (Table 4).
Analysis of a marketed preparation
The results obtained for the amount of fenofibrate in tablets as against 
the label claims were in good agreement signifying that there is no 
interference from any of the excipients presents in tablets. The percent 
assay was found to be 98.47%, for fenofibrate, in marketed formulation 
in six replicate determinations.
CONCLUSION
In the present research work, an attempt has been made to develop 
and validate a quick, precise, and accurate method based on normal-
phase HPTLC has been developed for routine analysis of fenofibrate 
in fixed-dose combination tablets. The method was validated for 
linearity, precision, accuracy, and specificity. It is cheap, quick and does 
not use chloroform and combination of solvents, therefore, suitable 
for routine analysis of fenofibrate in fixed-dose combination tablets. 
When compared with the reported HPTLC method, the developed 
HPTLC method is both time and cost-effective for the determination of 
fenofibrate.
ACKNOWLEDGMENTS
Authors are also thankful to Principal Dr. (Mrs.) KiranBhise, the 
Management of M.C.E. Society’s Allana College of Pharmacy, Pune, 
India, for providing necessary research facilities and Public Testing 
Laboratory, Erandwane, Pune, Maharashtra, India, for providing 
technical support and facilities to carry out research work. The authors 
also express their gratitude to Emcure Pharmaceuticals Limited, Pune, 
Maharashtra, India, for providing a gift sample of pure drugs.
CONFLICT OF INTERESTS
The authors have no conflict of interest.
REFERENCES
1. Potawale RS, Gabhe SY. HPTLC method for simultaneous determination 
of rosuvastatin and fenofibrate in bulk and pharmaceutical formulation. 
Int J Pharm Pharm Sci 2014;6:323-6.
2. Budavari S. The Merck Index: An Encyclopedia of Chemicals, Drugs 
and Biological. Vol. 4. Whitehouse Station: Merck and Co.; 1996. 
p. 3978.
3. British Pharmacopoeia. British Pharmacopoeia Commission Secretariat 
of the Medicines and Healthcare products Regulatory Agency. Vol. 4. 
London: Stationary Office; 2009. p. 2456.
4. Gupta KR, Askarkar SS, Rathod PP, Wadodkar SG. Validated 
spectrophotometric determination of fenofibrate in formulation. Pharm 
Sin 2010;1:173-8.
5. Kondawar MS, Kamble KG, Maharshi KH, Khandare MM. UV 
Spectrophotometric estimation of ezetimibe and fenofibrate in bulk 
drug and dosage form using simultaneous equation method. Int J 
Chemtech Res 2011;3:749-54.
6. Sevda RR, Ravetkar AS, Shirote PJ. UV spectrophotometric estimation 
of rosuvastatin calcium and fenofibrate in bulk drug and dosage 
form using simultaneous equation method. Int J Chemtech Res 
2011;3:629-35.
7. Mandwal PS, Patel PR, Agarwal KM, Surana SJ. Q-Absorbance and 
multicomponent UV-spectrophotometric methods for simultaneous 
estimation of rosuvastatin calcium and fenofibrate in pharmaceutical 
formulation. Pharm Lett 2012;4:1054-9.
8. Fathy MM, Mohamed WI, Mohie MK, Khalid AM, Mohamed YK. 
Determination of fenofibrate and the degradation product using 
simultaneous UV-derivative spectrometric method and HPLC. Am J 
Anal Chem 2011;2:332-43.
9. Khaleel N, Rahaman A. Validated stability indicating RP-HPLC 
method for simultaneous determination of atorvastatin, fenofibrate 
and folic acid in bulk and pharmaceutical dosage form. Pharm Lett 
2016;8:13-32.
10. Gurram SC. RP-HPLC method development and validation for the 
simultaneous estimation of atorvastatin, fenofibrate and ezetimibe in a 
pharmaceutical dosage form. Biochem Anal Biochem 2015;4:1-4.
11. Rekha R, Kuma PR. Validated stability-indicating isocratic RP-HPLC 
method of determination of rosuvastatin calcium and fenofibrate in 
bulk and in solid dosage by vieordt’s method. Am J Pharmtech Res 
2017;7:465-78.
12. Abid MY, Dong WK, Han GC, Euichaul O. Validation of a highly 
sensitive RP-HPLC method for quantification of fenofibrate in pure and 
pharmaceutical dosage forms. Curr Pharm Anal 2014;10:97-104.
13. Samyukta E, Srinivas P. Stability indicating method development and 
Table 2: Intra‑ and inter‑day precision of the HPTLC 
method (n=6)
Drug Actual concentration 
intra‑/inter‑daya
Intra‑/inter‑day (%) RSD
Fenofibrate 100 98.52/99.34 0.69/1.00
n: Number of determinations, a: ng band−1, RSD: Relative standard deviation. 
HPTLC: High-performance thin-layer chromatographic








100 80 179.06 99.48±0.93
100 100 200.43 100.21±1.09
100 120 218.96 99.53±0.86
n: Number of determinations, a: ng band−1, RSD: Relative standard deviation
Table 4: Robustness testing (n=6, 100 ng band−1)
Parameter varied % RSD
Mobile phase (ethyl acetate) 
composition (±0.1 ml)
0.50
Amount of mobile phase (±5%) 1.01
Time from band application to 
chromatography (±10 min)
0.47
Time from chromatography to 
scanning (±15 min)
0.83
n: Number of determinations, RSD: Relative standard deviation
150
Asian J Pharm Clin Res, Vol 11, Issue 5, 2018, 147-150
 Potawale and Hangad 
validation of choline fenofibrate in pharmaceutical dosage forms by 
RP-HPLC. Int J Pharm Sci Res 2014;5:849-54.
14. Sahu PK, Murthy Pyla SR, Srinivas K, Swain S. Simultaneous RP-
HPLC method development and validation of atorvastatin, ezetimibe 
and fenofibrate. Pharm Reg Aff 2016;5:1-6.
15. Bhinge SD, Malipatil SM, Jondhale A, Hirave R, Savalia S. New 
approach to the RP-HPLC method for simultaneous estimation of 
atorvastatin calcium and fenofibrate in pharmaceutical dosage forms. 
Eur J Chem 2012;9:1223-9.
16. Karunakaran A, Subhash V, Chinthala R, Muthuvijayan J. Simultaneous 
estimation of rosuvastatin calcium and fenofibrate in bulk and in tablet 
dosage form by UV-spectrophotometry and RP-HPLC. J Pharm Sci 
2011;4:58-63.
17. Macwana CR, Patel AJ, Parmar VM, Patel SG. Simultaneous HPTLC 
analysis of atorvastatin calcium, ezetimibe, and fenofibrate in tablet. 
J Liq Chromatogr Relat Technol 2012;35:524-32.
18. Rao S, Rao P, Dadhich AS, Rao MK. Simultaneous determination 
of atorvastatin, ezetimibe and fenofibrate in tablets by planar 
chromatography with confirmation by electrospray ionization mass 
spectrometry. Int J Res Pharm Chem 2017;7:51-9.
19. Ramadan AA, Mandil H, Abu-Saleh R. Development and validation 
of differential pulse polarographic analysis of fenofibrate in pure and 
pharmaceutical dosage forms using dropping mercury electrode. Int J 
Pharm Pharm Sci 2016;8:284-9.
20. International Conference on Harmonization. ICH Harmonized Tripartite 
Guideline Validation of Analytical Procedures: Text and Methodology 
Q2 (R1). Geneva: ICH; 2005.
